Swedish Orphan Biovitrum AB (SOBI) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SOBI Analyst Ratings

Strong Buy

4 Buy

1 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Swedish

Orphan Biovitrum AB

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SOBI Stock 12 Month Forecast

Average Price Target

kr341.00

▲(24.45% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Swedish Orphan Biovitrum AB in the last 3 months. The average price target is kr341.00 with a high forecast of kr370.00 and a low forecast of kr285.00. The average price target represents a 24.45% change from the last price of kr274.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"277":"kr277","324":"kr324","371":"kr371","300.5":"kr300.5","347.5":"kr347.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":370,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr370.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":341,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr341.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr285.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[277,300.5,324,347.5,371],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,285.2,291.7230769230769,298.24615384615385,304.7692307692308,311.2923076923077,317.81538461538463,324.3384615384615,330.86153846153843,337.38461538461536,343.9076923076923,350.4307692307692,356.95384615384614,363.4769230769231,{"y":370,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,285.2,289.4923076923077,293.7846153846154,298.0769230769231,302.36923076923074,306.66153846153844,310.95384615384614,315.24615384615385,319.53846153846155,323.83076923076925,328.12307692307695,332.4153846153846,336.7076923076923,{"y":341,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,285.2,285.18461538461537,285.16923076923075,285.15384615384613,285.1384615384615,285.1230769230769,285.1076923076923,285.0923076923077,285.0769230769231,285.0615384615385,285.04615384615386,285.03076923076924,285.0153846153846,{"y":285,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":285.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":309,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":305,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":285.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr370.00

Average Price Targetkr341.00

Lowest Price Targetkr285.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

kr300

Hold

9.49%

Upside

Reiterated

08/06/25

Swedish Orphan Biovitrum AB's strong financial performance is the primary driver of its stock score, supported by robust profitability and a solid balance sheet. However, technical analysis indicates bearish momentum, which tempers the overall score. The valuation is moderate, with no dividend yield to attract income investors. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Alistair CampbellRBC Capital

RBC Capital

kr345→kr350

Buy

27.74%

Upside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Jon BerggrenKepler Capital

Kepler Capital

kr350

Buy

27.74%

Upside

Reiterated

07/16/25

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Harry GillisBerenberg Bank

Berenberg Bank

kr370

Buy

35.04%

Upside

Reiterated

07/16/25

Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

kr285

Hold

4.01%

Upside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Shirley ChenBarclays

Barclays

kr350

Buy

27.74%

Upside

Reiterated

06/16/25

Barclays Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)

Patrik LingDNB Markets

DNB Markets

kr365

Buy

33.21%

Upside

Reiterated

04/03/25

DNB Markets Reiterates Buy Rating on Swedish Orphan Bio (SOBI:SS) (SWTUY)DNB Markets analyst Patrik Ling reiterated a Buy rating and SEK365.00 price target on Swedish Orphan Bio (SOBI:SS) (OTC: SWTUY).

Brian BalchinJefferies

Jefferies

kr310→kr308

Hold

12.41%

Upside

Reiterated

01/07/25

Swedish Orphan Bio (SOBI:SS) (SWTUY) PT Lowered to SEK308 at JefferiesJefferies analyst Brian Balchin lowered the price target on Swedish Orphan Bio (SOBI:SS) (OTC: SWTUY) to SEK308.00 (from SEK310.00) while maintaining a Hold rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

kr300

Hold

9.49%

Upside

Reiterated

08/06/25

Alistair CampbellRBC Capital

RBC Capital

kr345→kr350

Buy

27.74%

Upside

Reiterated

07/22/25

RBC Capital Sticks to Its Buy Rating for Swedish Orphan Biovitrum AB (0MTD)

Jon BerggrenKepler Capital

Kepler Capital

kr350

Buy

27.74%

Upside

Reiterated

07/16/25

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Harry GillisBerenberg Bank

Berenberg Bank

kr370

Buy

35.04%

Upside

Reiterated

07/16/25

Swedish Orphan Biovitrum AB (0MTD) Receives a Buy from Berenberg Bank

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

kr285

Hold

4.01%

Upside

Upgraded

07/08/25

Swedish Orphan Biovitrum AB (0MTD) was upgraded to a Hold Rating at Deutsche Bank

Shirley ChenBarclays

Barclays

kr350

Buy

27.74%

Upside

Reiterated

06/16/25

Barclays Remains a Buy on Swedish Orphan Biovitrum AB (0MTD)

Patrik LingDNB Markets

DNB Markets

kr365

Buy

33.21%

Upside

Reiterated

04/03/25

Brian BalchinJefferies

Jefferies

kr310→kr308

Hold

12.41%

Upside

Reiterated

01/07/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Swedish Orphan Biovitrum AB

1 Month

xxx

Success Rate

4/8 ratings generated profit

Average Return

+0.86%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.86% per trade.

3 Months

xxx

Success Rate

9/18 ratings generated profit

Average Return

-0.14%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.14% per trade.

1 Year

Alistair CampbellRBC Capital

Success Rate

8/18 ratings generated profit

Average Return

+7.54%

reiterated a buy rating 18 days ago

Copying Alistair Campbell's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +7.54% per trade.

2 Years

xxx

Success Rate

6/18 ratings generated profit

Average Return

+0.45%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +0.45% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SOBI Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SOBI has received 16 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. SOBI average Analyst price target in the past 3 months is 341.00.

Each month's total comprises the sum of three months' worth of ratings.

SOBI Financial Forecast

SOBI Earnings Forecast

Next quarter’s earnings estimate for SOBI is kr4.85 with a range of kr4.44 to kr5.12. The previous quarter’s EPS was kr1.83. SOBI beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.46% of the time in the same period. In the last calendar year SOBI has Outperformed its overall industry.

SOBI Sales Forecast

Next quarter’s sales forecast for SOBI is kr7.81B with a range of kr7.33B to kr8.67B. The previous quarter’s sales results were kr6.17B. SOBI beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.05% of the time in the same period. In the last calendar year SOBI has Outperformed its overall industry.

SOBI Stock Forecast FAQ

What is SE:SOBI’s average 12-month price target, according to analysts?

Based on analyst ratings, Swedish Orphan Biovitrum AB’s 12-month average price target is 341.00.

What is SE:SOBI’s upside potential, based on the analysts’ average price target?

Swedish Orphan Biovitrum AB has 24.45% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Swedish Orphan Biovitrum AB a Buy, Sell or Hold?

Swedish Orphan Biovitrum AB has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.

What is Swedish Orphan Biovitrum AB’s share price target?

The average share price target for Swedish Orphan Biovitrum AB is 341.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr370.00 ,and the lowest forecast is kr285.00. The average share price target represents 24.45% Increase from the current price of kr274.

What do analysts say about Swedish Orphan Biovitrum AB?

Swedish Orphan Biovitrum AB’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Swedish Orphan Biovitrum AB?

To buy shares of SE:SOBI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Swedish Orphan Biovitrum AB (SOBI) Stock Forecast & Price Target

SOBI Analyst Ratings

SOBI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Swedish Orphan Biovitrum AB

SOBI Analyst Recommendation Trends

SOBI Financial Forecast

SOBI Earnings Forecast

SOBI Sales Forecast

SOBI Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts